Sunovion's Lonhala Magnair inhalation solution was approved by the FDA as a treatment for patients with chronic obstructive pulmonary disease. The company intends to launch the drug in early 2018.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.